Brian Pearlman1, Michael Perrys2, Andrew Hinds3. 1. Center for Hepatitis C, Wellstar Atlanta Medical Center, Medical College of Georgia, Department of Medicine, Emory School of Medicine, Atlanta, Georgia, USA. 2. Department of Medicine, Medical College of Georgia, Augusta, Georgia, USA. 3. Center for Hepatitis C, Wellstar Atlanta Medical Center, Mercer School of Medicine, Macon, Georgia, USA.
Abstract
OBJECTIVES: Chronic hepatitis C-infected patients who do not respond to nonstructural 5A inhibitor-containing regimens have few treatment options. It is unclear if patients who fail glecaprevir/pibrentasvir (G/P) (Mavyret) can be re-treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) because the latter's registration trials antedated the availability of the former. METHODS: Adherent virologic failures to G/P were re-treated with 12 weeks of SOF/VEL/VOX, and all subjects underwent resistance testing at baseline and again with subsequent relapse. RESULTS: Ninety-four percent of subjects achieved sustained virologic response with re-treatment, despite 90% of 31 subjects harboring nonstructural 5A inhibitor resistance-associated mutations at baseline. DISCUSSION: SOF/VEL/VOX is an effective regimen for virologic failures to G/P.
OBJECTIVES:Chronic hepatitis C-infectedpatients who do not respond to nonstructural 5A inhibitor-containing regimens have few treatment options. It is unclear if patients who fail glecaprevir/pibrentasvir (G/P) (Mavyret) can be re-treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) because the latter's registration trials antedated the availability of the former. METHODS: Adherent virologic failures to G/P were re-treated with 12 weeks of SOF/VEL/VOX, and all subjects underwent resistance testing at baseline and again with subsequent relapse. RESULTS: Ninety-four percent of subjects achieved sustained virologic response with re-treatment, despite 90% of 31 subjects harboring nonstructural 5A inhibitor resistance-associated mutations at baseline. DISCUSSION: SOF/VEL/VOX is an effective regimen for virologic failures to G/P.